Mbeutcha Aurélie, Mathieu Romain, Rouprêt Morgan, Gust Kilian M, Briganti Alberto, Karakiewicz Pierre I, Shariat Shahrokh F
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; ; Department of Urology, University of Nice Sophia-Antipolis, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, Nice, France.
Department of Urology, Rennes University Hospital, Rennes, France.
Transl Androl Urol. 2016 Oct;5(5):720-734. doi: 10.21037/tau.2016.09.07.
In the context of customized patient care for upper tract urothelial carcinoma (UTUC), decision-making could be facilitated by risk assessment and prediction tools. The aim of this study was to provide a critical overview of existing predictive models and to review emerging promising prognostic factors for UTUC. A literature search of articles published in English from January 2000 to June 2016 was performed using PubMed. Studies on risk group stratification models and predictive tools in UTUC were selected, together with studies on predictive factors and biomarkers associated with advanced-stage UTUC and oncological outcomes after surgery. Various predictive tools have been described for advanced-stage UTUC assessment, disease recurrence and cancer-specific survival (CSS). Most of these models are based on well-established prognostic factors such as tumor stage, grade and lymph node (LN) metastasis, but some also integrate newly described prognostic factors and biomarkers. These new prediction tools seem to reach a high level of accuracy, but they lack external validation and decision-making analysis. The combinations of patient-, pathology- and surgery-related factors together with novel biomarkers have led to promising predictive tools for oncological outcomes in UTUC. However, external validation of these predictive models is a prerequisite before their introduction into daily practice. New models predicting response to therapy are urgently needed to allow accurate and safe individualized management in this heterogeneous disease.
在上尿路尿路上皮癌(UTUC)的个性化患者护理背景下,风险评估和预测工具有助于决策制定。本研究的目的是对现有的预测模型进行批判性综述,并回顾UTUC新出现的有前景的预后因素。使用PubMed对2000年1月至2016年6月以英文发表的文章进行文献检索。选取了关于UTUC风险组分层模型和预测工具的研究,以及与晚期UTUC和术后肿瘤学结局相关的预测因素和生物标志物的研究。已经描述了各种用于晚期UTUC评估、疾病复发和癌症特异性生存(CSS)的预测工具。这些模型大多基于肿瘤分期、分级和淋巴结(LN)转移等公认的预后因素,但也有一些整合了新描述的预后因素和生物标志物。这些新的预测工具似乎具有较高的准确性,但缺乏外部验证和决策分析。患者、病理和手术相关因素与新型生物标志物的结合,为UTUC的肿瘤学结局带来了有前景的预测工具。然而,在将这些预测模型引入日常实践之前,对其进行外部验证是先决条件。迫切需要新的预测治疗反应的模型,以便在这种异质性疾病中进行准确和安全的个体化管理。